From conventional to stealth liposomes : a new Frontier in cancer chemotherapy
In this review, the different types of liposome used in medicine, in particular in the field of antitumor therapy, are focalised, emphasizing their structures, pharmacological action, pharmacokinetics and biodistribution, toxicity profiles and in the main clinical applications. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation liposomes were pegylated liposomal doxorubicin (Caelix), called "stealth liposomes" because of their ability to evade interception by the immune system, characterized by very long-circulation half-life, favourable pharmacokinetic behaviour and specific accumulation in tumor tissues.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 Suppl 4 |
|---|---|
| Enthalten in: |
Journal of chemotherapy (Florence, Italy) - 16 Suppl 4(2004) vom: 18. Nov., Seite 94-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cattel, L [VerfasserIn] |
|---|
| Themen: |
80168379AG |
|---|
| Anmerkungen: |
Date Completed 01.04.2005 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM153468874 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM153468874 | ||
| 003 | DE-627 | ||
| 005 | 20231223064059.0 | ||
| 007 | tu | ||
| 008 | 231223s2004 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0512.xml |
| 035 | |a (DE-627)NLM153468874 | ||
| 035 | |a (NLM)15688621 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cattel, L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From conventional to stealth liposomes |b a new Frontier in cancer chemotherapy |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2005 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In this review, the different types of liposome used in medicine, in particular in the field of antitumor therapy, are focalised, emphasizing their structures, pharmacological action, pharmacokinetics and biodistribution, toxicity profiles and in the main clinical applications. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation liposomes were pegylated liposomal doxorubicin (Caelix), called "stealth liposomes" because of their ability to evade interception by the immune system, characterized by very long-circulation half-life, favourable pharmacokinetic behaviour and specific accumulation in tumor tissues | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 700 | 1 | |a Ceruti, M |e verfasserin |4 aut | |
| 700 | 1 | |a Dosio, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of chemotherapy (Florence, Italy) |d 1989 |g 16 Suppl 4(2004) vom: 18. Nov., Seite 94-7 |w (DE-627)NLM012678473 |x 1973-9478 |7 nnns |
| 773 | 1 | 8 | |g volume:16 Suppl 4 |g year:2004 |g day:18 |g month:11 |g pages:94-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 Suppl 4 |j 2004 |b 18 |c 11 |h 94-7 | ||